EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Eradivir
company
Eradivir, a clinical-stage biotechnology company, closed a $10 million private financing round to support its immune‑based therapeutic development. The round was announced on 2025-10-07; no investors were disclosed in the release.
Want to join the conversation?
Loading comments...
Comments
Want to join the conversation?
Loading comments...